Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: New drugs and new ideas are transforming acute myeloid #leukemia #leusm https://t.co/XpUGh0zLG9
SteveFDA (R-D.C.)
@SGottliebFDA
RT @califf001: This is a really important and rewarding job. If you love drug development, clinical evaluation, collaboration with patient… QT @FDAJobs: One more week to complete the application for the Director, Office of New Drugs. Apply here: https://t.co/jyhNXscu7e)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: OUTBREAK UPDATE: #FDA confirmed cyclospora in Fresh Express salad mix used in recalled McDonald’s salads. No produc… https://t.co/5FiPGYDRq1
SteveFDA (R-D.C.)
@SGottliebFDA
FDA draft guidance on Patient-Focused Drug Development: Collecting Comprehensive and Representative Input #PFDD https://t.co/hdEbvy76hw https://t.co/PgnKA3CUWE
SteveFDA (R-D.C.)
@SGottliebFDA
Learn how FDA’s history has shaped our past… and enriches our future. Check out these short videos featuring some interesting items in FDA’s history vault. https://t.co/JJsttoSBJR https://t.co/k6KEkb20b5
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAfood: FDA #FoodSafety Plan Builder is a free desktop app to help #foodmanufacturers develop a plan specific to their faci… https://t.co/ZN3vnUBErt
SteveFDA (R-D.C.)
@SGottliebFDA
Tomorrow #FDA holds an advisory committee meeting on the transmucosal immediate-release fentanyl medicines’ (TIRF) risk evaluation and mitigation strategy (REMS). My statement on the AdCom and our continued efforts to evaluate and improve the TIRF REMS https://t.co/dZaosX0Zk4 https://t.co/7faEYTO06y
SteveFDA (R-D.C.)
@SGottliebFDA
My Statement: Our risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products is an important tool for helping to ensure safe use and reduce risk of abuse/misuse. Making sure they’re achieving their purpose is critical https://t.co/dZaosX0Zk4
SteveFDA (R-D.C.)
@SGottliebFDA
Immunizations can prevent a variety of diseases and innovation in this field continues to save lives. #FDA provides the guidance and expertise necessary to continue fostering vaccine development and ensure their safety and effectiveness #NIAM18 https://t.co/ISYqrSnIEB
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: My Statement: Our risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products is a… https://t.co/ibLUucOYKK
SteveFDA (R-D.C.)
@SGottliebFDA
RT @SGottliebFDA: Tomorrow #FDA holds an advisory committee meeting on the transmucosal immediate-release fentanyl medicines’ (TIRF)… https://t.co/CSBLOMY2kF
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: A new blog by FDA Commissioner @SGottliebFDA and CTP Director Mitch Zeller announces several new initiatives and up… https://t.co/RDIeKGcXr9
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: OUTBREAK Update: As of August 2, @CDCgov reports 395 lab confirmed cases of #Cyclospora – 16 hospitalized, no death… https://t.co/pL0QWe9r3C
SteveFDA (R-D.C.)
@SGottliebFDA
THREAD: 1/2 Our risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl (TIRF) products is an important tool for helping to ensure safe use and reduce risk of abuse/misuse. Making sure they’re achieving their purpose is critical https://t.co/dZaosX0Zk4
SteveFDA (R-D.C.)
@SGottliebFDA
2/2 With any REMS, our goal is to achieve a public health purpose. We’re seeking expert advice on whether new approaches to this program will put #FDA on the right path to balancing patient access to TIRF meds with measures to reduce known serious risks: https://t.co/dZaosX0Zk4
SteveFDA (R-D.C.)
@SGottliebFDA
My statement: Our adcom today on the REMS for transmucosal immediate-release fentanyl products is part of our broader effort to make sure it’s achieving its public health goal, provide transparency on what’s working and what’s not, address shortcomings https://t.co/vD2U2tKTN5
SteveFDA (R-D.C.)
@SGottliebFDA
RT @DrNancyM_CDC: In 1980, #smallpox became 1st and only vaccine-preventable disease to be eradicated. Let’s make #polio the second.… https://t.co/S7iqTi4TaY
SteveFDA (R-D.C.)
@SGottliebFDA
RT @califf001: Ms Meyer sets the example for public service-working for the public health in different administrations with distinction. G… QT @FDASpox: Today @SGottliebFDA took the op to honor his staff for their extraordinary efforts & commitment to public service.… https://t.co/b3auP0ywkj)
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: Updates and new initiatives from the FDA on the anniversary of the Family Smoking Prevention and Tobacco Control Ac… https://t.co/Ii7crPyPaT
SteveFDA (R-D.C.)
@SGottliebFDA
We’re releasing the 1st of two guidances aimed at supporting the development of novel, inhaled nicotine replacement therapies that could be submitted to the FDA for approval as new drugs, similar to current over-the-counter pharmaceutical NRT products: https://t.co/kvPriTO5xg